Colircusi Cicloplejico

Quick links

Choose a section

Quick links to important sections

Advertisements

Colircusi Cicloplejico

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Colircusi Cicloplejico

Property Description
Active ingredient Cyclopentolate hydrochloride
Form Ophthalmic Solution (Eye Drops)
Pharmacological class Anticholinergic Agent / Muscarinic Antagonist
Common use Diagnostic eye examination (Refraction and fundus checks)
Origin Synthetic

What Type of Medication is Colircusi Cicloplejico?

Colircusi Cicloplejico is a prescription-only ophthalmic solution containing Cyclopentolate hydrochloride, and it is classified pharmacologically as an anticholinergic agent, specifically a muscarinic antagonist. This preparation is a specialized pharmaceutical designed for topical ocular use. The classification as an anticholinergic agent defines its core function: blocking the action of specific neurotransmitters within the ocular structures. Cyclopentolate hydrochloride, its single active ingredient, is a synthetic small molecule developed to induce temporary changes required for detailed eye assessment. Cyclopentolate is recognized for its essential use in diagnostic mydriasis and cycloplegia. This status reflects the drug's established use for crucial diagnostic purposes, a fact supported by extensive clinical recognition in the field.


Composition and Physical Form

The core component of the ophthalmic solution is the active ingredient, Cyclopentolate hydrochloride. Colircusi Cicloplejico is formulated as a sterile, aqueous solution (eye drops), ensuring safe and effective delivery to the eye. This single active ingredient product uses a specialized, borate-buffered aqueous base as its vehicle, along with inactive components, such as a preservative, to maintain sterility and the appropriate chemical environment for ocular application. The liquid form allows for rapid, efficient dispersion across the cornea and quick absorption by the target tissues.


Primary Purpose of the Cycloplegic Effect

The general purpose of this medication is to cause temporary, non-surgical alterations in the eye required for specialized diagnostic ophthalmic procedures. Its administration induces two primary effects: mydriasis (pupillary dilation) and cycloplegia (temporary paralysis of the ciliary focusing muscle). These combined physiological actions are essential because they allow eye care professionals to perform a detailed and unobstructed examination of the eye's internal structures. Furthermore, Cyclopentolate is clinically recognized for its efficacy in inducing cycloplegia for the purpose of accurate refraction in children and adults. This effect facilitates obtaining the most accurate prescription for corrective lenses by relaxing the eye's natural accommodation reflex.

Regulatory References

  1. World Health Organization (WHO) Essential Medicines List
  2. WHO Essential Medicines List for Cyclopentolate
Advertisements

What side effects are possible with Colircusi Cicloplejico?

Possible Side Effects and Safety Information

The safety profile of Cyclopentolate hydrochloride (Colircusi Cicloplejico) is primarily characterized by effects related to its anticholinergic action, influencing both the eye and the body's systemic functions, as classified in official regulatory documents.


Adverse Reactions by Frequency and System-Organ Class

Adverse reactions are formally grouped by the affected body system (System-Organ Class or SOC) and their documented frequency.

  • Common Effects (Eye Disorders): The most frequently documented reactions are transient ocular irritation, such as burning or stinging upon instillation, blurred vision due to cycloplegia, and photophobia (sensitivity to light) due to pupillary dilation.
  • Uncommon/Rare Systemic Effects: Less frequently, systemic effects reflecting muscarinic antagonism may occur, affecting the Nervous System (dizziness, headache, dry mouth) and, rarely, the Cardiac System (tachycardia) and Gastrointestinal System (nausea, vomiting, decreased motility).

Serious Adverse Reactions and Population-Specific Safety

Official labeling documents address the potential for rare but serious adverse reactions, which are often related to systemic absorption.

  • Serious Adverse Reactions: Severe systemic toxicity includes the potential for Central Nervous System (CNS) disturbances, such as psychotic reactions and seizures. There is a documented risk of precipitating acute angle-closure glaucoma in predisposed patients.
  • Population-Specific Risk: Regulatory sources note the increased susceptibility to systemic toxicity in the pediatric population, particularly infants and young children, who are more prone to severe CNS and cardiorespiratory effects. Caution is also warranted for older adults due to the glaucoma risk.

Safety Restrictions and Limitations

The medication is contraindicated in patients with known or suspected narrow-angle or angle-closure glaucoma. Furthermore, due to the potential for compounded effects, caution is advised when using this drug concurrently with other medications that possess anticholinergic activity.

Advertisements

Overdose and Emergency Response

Overdose with Cyclopentolate hydrochloride ophthalmic solution results from systemic absorption, leading to severe anticholinergic toxicity. Immediate medical attention is required upon suspicion of an overdose or accidental ingestion, particularly if life-threatening signs are present. Close observation of infants for at least 30 minutes following instillation is officially mandated to detect systemic absorption promptly.

Documented Overdose Manifestations

Classification Official Regulatory Findings
Central Nervous System (CNS) Disorientation, hallucinations, incoherent speech, restlessness, seizures/convulsions, and abnormal behavior.
Systemic Anticholinergic Tachycardia, hyperpyrexia (fever), flushing of the face, dry mouth/skin, and urinary retention.
Infant-Specific Abdominal distension, vomiting, and feeding intolerance.

Severe Outcomes and Emergency Management

Severe intoxication is officially documented to escalate to coma, medullary paralysis, and circulatory and respiratory failure, which may result in death. The documentation explicitly notes that infants, young children, and children with conditions such as Down syndrome or cerebral damage have an increased susceptibility to these severe outcomes.

The official label lists Physostigmine salicylate as the specific antidote of choice for managing severe manifestations of toxicity. Treatment involves general symptomatic and supportive care, as documented in regulatory information. Individuals should contact emergency services immediately if accidental ingestion or a significantly excessive dose is suspected.

Advertisements

Therapeutic Uses of Colircusi Cicloplejico

What Colircusi Cicloplejico Treats: Main Uses and Benefits

The primary therapeutic role of Colircusi Cicloplejico (Cyclopentolate hydrochloride) is applied across domains where additional symptomatic support is needed, particularly within ophthalmology, and is associated with two important therapeutic and diagnostic benefits. This medication is commonly used across conditions presenting with acute episodes and is relevant in clinical settings where supportive symptomatic assistance is needed for accurate ocular assessment. The medication is primarily indicated for diagnostic purposes but may also be applied in situations involving certain distressing symptoms like uveitis (swelling and inflammation of the eye).


Key Applications and Symptomatic Relief

The medication is commonly used for managing symptoms associated with cycloplegic refraction procedures and for the supportive treatment of anterior uveitis (including iritis and iridocyclitis).

This supportive use is critical in managing symptoms related to inflammatory or irritative states and helps address the severe ocular pain caused by ciliary muscle spasm. The action of the medication may contribute to easing the overall symptom load in clinical settings marked by temporary physiological imbalance, helping to maintain a sense of stability when symptoms are more noticeable.

“The medication helps support the process of obtaining an accurate prescription for corrective lenses, assisting with maintaining functional stability and visual clarity.”

Quick Fact: Relief for Painful Ciliary Muscle Spasm

Regulatory References

  1. NIH MedlinePlus overview of Cyclopentolate
Advertisements

Eligibility and Restrictions for Use

Colircusi Cicloplejico, which contains cyclopentolate hydrochloride, is typically used to dilate the pupil (mydriasis) and temporarily paralyze the eye's focusing muscles (cycloplegia) for eye examinations or to treat certain eye inflammations.


Who Cannot Use It (Contraindications)

This medication is generally not recommended for patients with:

  • Angle-Closure Glaucoma: Especially untreated narrow-angle glaucoma or anatomically narrow angles, as the medication can increase intraocular pressure and potentially trigger an acute attack.
  • Hypersensitivity: Individuals with a known allergy to cyclopentolate or any component of the formulation.
  • Certain Children: Cyclopentolate is generally contraindicated in premature infants and small infants under three months old due to an increased risk of severe systemic side effects.

Use with Caution (Special Populations)

Healthcare providers must exercise caution when prescribing this medicine to specific patient groups due to a higher risk of adverse effects:

Patient Group Concern
Children (especially young, fair-skinned) Increased risk of central nervous system (CNS) disturbances, such as behavioral changes or seizures.
Individuals with Down Syndrome Predisposition to angle-closure glaucoma and increased risk of CNS and systemic side effects.
Elderly Patients (over 65 years) May be more susceptible to increased intraocular pressure.
Individuals with Spastic Paralysis, Brain Damage, or Certain Cardiovascular Disorders Increased susceptibility to adverse reactions.

It is essential to inform your doctor about any pre-existing medical conditions, especially glaucoma or a history of severe reactions to atropine, as well as if you are pregnant or breastfeeding.

Advertisements

What should I know about interactions with other medicines?

Colircusi Cicloplejico (Cyclopentolate hydrochloride) interactions are classified primarily as pharmacodynamic interactions stemming from its action as an anticholinergic agent, as documented in official regulatory prescribing information.

Documented Pharmacodynamic Interactions

Co-administration with other medicinal products that possess anticholinergic properties (such as certain tricyclic antidepressants, some antihistamines, phenothiazines, or amantadine) may result in a formal augmentation of antimuscarinic effects. Regulatory agencies note that this additive effect can increase the risk of systemic anticholinergic disturbances.

Conversely, Cyclopentolate is documented to antagonize the therapeutic effects of specific ocular cholinergic agents. These include miotic eye drops such as Pilocarpine and Carbachol, as well as ophthalmic cholinesterase inhibitors. Co-administration with these agents may reduce their intended ocular action.

Other Interaction Conditions

No clinically significant pharmacokinetic interactions involving metabolic enzymes or transporters are formally documented. Interaction information for food, alcohol, or herbal products is not explicitly cited in major regulatory labels.

One timing-based condition is specified: for infants, feeding should be withheld for four hours following ophthalmic administration due to documented potential for feeding intolerance. Furthermore, systemic absorption is a heightened consideration for populations such as children with Down's Syndrome or spastic paralysis, increasing the clinical relevance of co-administered anticholinergic drugs.

Advertisements

Mechanism of Action

Colircusi Cicloplejico contains cyclopentolate, which functions as a muscarinic antagonist. Upon topical ophthalmic administration, the molecule is selectively delivered to ocular smooth muscle tissues, primarily the iris sphincter muscle and the ciliary body. Cyclopentolate engages with and competitively inhibits muscarinic acetylcholine receptors (M-receptors), particularly subtypes M1 and M5, located on these target muscles.

This antagonism prevents the binding of the endogenous neurotransmitter acetylcholine. The resulting lack of cholinergic stimulation leads to a reduction in intracellular calcium flux and subsequent relaxation of the smooth muscle fibers. Relaxation of the iris sphincter muscle causes mydriasis (pupil dilation). Concurrently, the relaxation of the ciliary muscle inhibits its contraction, resulting in the abolition of accommodation, a system-level physiological consequence known as cycloplegia.

Advertisements

Dosage and Administration Information

How to use Colircusi Cicloplejico (Cyclopentolate Hydrochloride)

This section outlines the administration instructions for Colircusi Cicloplejico. This medication is for topical ocular use only and must not be injected.


Official Administration Guidelines

Administration Scope Detail
Route Topical ocular use (applied to the eye).
Administration Method Instillation (application of drops).
Frequency Pattern As-needed for diagnostic procedures, with a possible single repeat dose within 5–10 minutes.
Preparation None required; the solution is ready-to-use.

Official Dosing and Procedural Rules

Dosing Schedule: The standard dosing involves instilling one or two drops of the solution (0.5%, 1%, or 2% strength) into the eye. This may be repeated five to ten minutes later if necessary.

Age-Specific Use Rules:

  • Adults and Adolescents: One or two drops, with possible repeat. Individuals with heavily pigmented irises may require a higher strength.
  • Small Infants: Administration is limited to a single instillation of one drop of 0.5% solution per eye.

Special Procedural Steps for Small Infants: To minimize the risk of systemic absorption, gentle pressure must be applied over the nasolacrimal sac (the inner corner of the eyelid near the nose) for two to three minutes immediately following the instillation of the drop. The infant should also be closely monitored for at least 30 minutes after the application.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Colircusi Cicloplejico


Evidence for Use in Diagnostic Eye Examinations (Cycloplegic Refraction)

The primary research base for Cyclopentolate hydrochloride involves its use in cycloplegic refraction, a state of temporary eye muscle relaxation that was examined as a component of refractive error measurement. This evidence relies on a collection of Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. Studies explored how researchers measured the time required to reach maximum cycloplegia (the relaxing of the eye's focusing power) and the resulting measurement patterns of a person's refractive error. Findings describe patterns observed in the studies related to the onset time and the duration of this acute diagnostic effect.


Evidence for Use in Supportive Management of Anterior Uveitis

Research has also explored the use of the eye drops in clinical settings involving anterior uveitis (inflammation of the front part of the eye). The evidence for this context largely comes from observational studies and systematic reviews of clinical data, rather than large-scale RCTs. Research examined outcomes related to physical discomfort, specifically the patterns of ocular pain reported in inflammatory states. Findings describe patterns observed when the eye drops were monitored alongside other standard treatments, but comparative evidence is limited regarding this context versus other treatment modalities.


Follow-up Duration and Research Gaps

The research for diagnostic use is focused on acute windows of examination, with follow-up durations typically limited to the hours following administration. Long-term effects are not fully established regarding the medication's overall impact, and there is limited information on the stability of resulting refractive prescriptions over months or years. Evidence quality also varies across studies, particularly for non-diagnostic contexts.


Evidence in Special Populations

Research has specifically explored the use of the eye drops in children, finding that patterns related to the onset of cycloplegia may differ based on individual characteristics like iris pigmentation (eye color). The data for certain groups, such as older adults or those with specific pre-existing eye conditions beyond the studied indications, remain insufficient.

Key Studies & References Cyclopentolate - Electronic Essential Medicines List (WHO EML) - Listing for Cycloplegic drug and Anterior uveitis

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Colircusi Cicloplejico (FAQ)

Q: Is it normal for the eyes to feel a little sensitive to light after using these drops?

According to official product information, photophobia (an increased sensitivity to light) is listed as a common effect following the use of these drops. This occurs because the medication dilates the pupil. Regulatory documents often suggest protective measures for the eyes when in bright light.

Q: How long does the effect of Colircusi Cicloplejico typically last?

The effects that relax the eye's focusing power (cycloplegia) typically last between 6 to 24 hours after the drops are applied. However, complete resolution of the full dilation of the pupil may take up to several days in some individuals, as described in regulatory documents.

Q: How quickly does Colircusi Cicloplejico start working after being applied?

The action of the medication begins rapidly. Studies summarized in official information indicate that the maximum effect on the eye's focusing muscle is typically reached within approximately 25 to 75 minutes after the drops are instilled.

Q: Is Colircusi Cicloplejico considered safe during pregnancy or breastfeeding?

Official sources note that well-controlled studies on its use during human pregnancy have not been conducted or are limited. It is also not fully known if the drug passes into human milk. Therefore, regulatory advice states that the drug should only be administered if a healthcare provider determines it is clearly needed.

Q: Can adults use Colircusi Cicloplejico or is it only for pediatric exams?

Colircusi Cicloplejico is officially indicated for use in both adults and children. It is used across various age groups to achieve the temporary effects of pupil dilation and cycloplegia for eye examinations.

Q: What other medicines are known to interact with Colircusi Cicloplejico?

The medicine is known to interact with other drugs that have anticholinergic properties, such as certain tricyclic antidepressants or some antihistamines. Combining these drugs can potentially increase the risk of systemic anticholinergic effects. It also lessens the therapeutic effect of certain eye drops used to constrict the pupil, like Pilocarpine.

Q: Is Colircusi Cicloplejico ever used for conditions other than eye exams?

Yes, regulatory documents indicate that in addition to its primary use in diagnostic eye examinations, the medication is sometimes used to assist in the supportive management of certain eye inflammations, such as uveitis (swelling and inflammation in the eye).

Q: Are headaches a potential side effect of Colircusi Cicloplejico?

Yes, official safety information lists headaches as a possible adverse effect that may occur following the use of these eye drops.

Q: Are the effects on the eyes temporary or long-lasting?

The drops are designed to produce effects that are temporary and not permanent. The drug's mechanism of action involves a transient blocking of signals to the eye muscles, with the effects generally lasting up to 24 hours.

Q: Is Colircusi Cicloplejico the same kind of drop as Atropine?

Both Cyclopentolate (the active ingredient in Colircusi Cicloplejico) and Atropine are categorized as anticholinergic agents. They share a similar pharmacological class, but Cyclopentolate is a synthetic drug designed to have a much quicker onset and shorter duration of action than Atropine.

Q: Are there different strengths or versions of Colircusi Cicloplejico?

Yes, official dosing information confirms that the ophthalmic solution is supplied in multiple concentrations. Common strengths mentioned in regulatory guidelines include 0.5%, 1%, and 2% solutions.

Q: Is there a link between Colircusi Cicloplejico and increased eye pressure?

Official warnings state that the drops may produce a transient elevation of intraocular pressure (pressure inside the eye). Because of this, the medication is formally contraindicated (not recommended) for patients with known or suspected narrow-angle glaucoma.

Q: Can wearing contact lenses affect the use of Colircusi Cicloplejico?

The solution contains a common preservative, benzalkonium chloride, which can be absorbed by soft contact lenses. Official warnings advise that contact lenses should be removed before instilling the drops and should not be reinserted until after a specified period of time.

Q: Are there foods or drinks that interact with Colircusi Cicloplejico?

Major regulatory labels do not explicitly cite pharmacokinetic interactions with food, alcohol, or herbal products. However, there is a distinct warning for infants that feeding should be withheld for four hours following administration due to the documented potential for feeding intolerance.

Q: Is a red or irritated eye a normal reaction to Colircusi Cicloplejico?

Mild eye irritation, including a transient burning or stinging sensation and some redness (hyperemia), is commonly documented in the side effects profile after instillation.

Q: Why is it sometimes used twice or three times during one visit?

The official administration guidelines allow the initial dose to be repeated after a short interval if necessary. This may be done to ensure the full effect is achieved, particularly in individuals with heavily pigmented irises (darker eye color).

Q: Does Colircusi Cicloplejico have a preservative, and what is it?

Yes, the solution is formulated with a preservative to help maintain sterility. The official labeling specifies that the preservative ingredient is benzalkonium chloride.

Q: Can I use sunglasses immediately after the eye drops are applied?

Since the drops cause the pupils to dilate, your eyes may become very sensitive to bright light. Regulatory information suggests that patients may protect their eyes with sunglasses or other measures against bright illumination while the dilation effects are present.

Q: Are there specific warnings for people with heart problems using the drops?

Regulatory warnings advise that the medication should be used with caution in patients with cardiovascular disorders. This is because systemic absorption may rarely cause cardiac symptoms such as tachycardia (a rapid heart rate).

Q: What are the key differences between Colircusi Cicloplejico and Cyclopentolate?

Cyclopentolate is the established active ingredient (Cyclopentolate hydrochloride) that produces the therapeutic effect. Colircusi Cicloplejico is a specific brand name under which this active ingredient is supplied as an ophthalmic solution.

Q: Is there a maximum amount of time Colircusi Cicloplejico can be stored after opening?

For multi-dose containers, official advice generally permits storage until the expiration date, provided the container is kept tightly closed and contamination is avoided. However, any single-dose units must always be immediately discarded after use to maintain safety and sterility.

Q: Is the medication available under different brand names in other countries?

Yes, the active ingredient, Cyclopentolate hydrochloride, is a common ophthalmic agent. It is available under various different brand names globally, such as Cyclogyl, Ak-Pentolate, and Cylate.

Q: Does Colircusi Cicloplejico contain any belladonna alkaloids?

Cyclopentolate is a synthetic anticholinergic agent, not a belladonna alkaloid itself. However, because it belongs to the same pharmacological class, official warnings advise caution in individuals known to be susceptible to belladonna alkaloids due to the potential for similar systemic effects.

Q: How common are serious side effects from Colircusi Cicloplejico?

Serious adverse reactions, such as Central Nervous System (CNS) disturbances, are generally documented as rare systemic events in official safety information. These effects are noted as being more likely to occur in susceptible patients, such as infants and young children.

Q: Is there a risk of permanent vision changes from using Colircusi Cicloplejico?

The drug's mechanism of action is limited to a temporary effect on the eye muscles, with the effects expected to resolve completely as the medication wears off. Official data suggests the changes are transient and not permanent under typical conditions of use.

Q: How is the active substance in Colircusi Cicloplejico eliminated from the body?

According to the pharmacokinetics information provided in some regulatory documents, the active substance is eliminated from the body primarily via the urine.

Q: What ingredients besides the active substance are in Colircusi Cicloplejico?

In addition to Cyclopentolate hydrochloride, the solution contains several inactive ingredients listed in official labeling. These include a borate-buffered aqueous base, the preservative benzalkonium chloride, boric acid, edetate disodium, and other components used for pH adjustment.

Advertisements

How should Colircusi Cicloplejico be stored and disposed of?

How to Store and Dispose of Colircusi Cicloplejico

Storage and disposal of Cyclopentolate hydrochloride ophthalmic solution must comply strictly with official regulatory requirements to ensure product stability and safety.

Official Storage Conditions

Requirement Description
Temperature Store at Controlled Room Temperature (20°C to 25°C or 68°F to 77°F), and keep from freezing.
Protection Must be stored away from heat, moisture, and protected from light.
Container The container must be kept tightly closed and stored in the original package.

Handling and Disposal

  • Child Safety: The medicine must be kept out of the reach of children.
  • Single-Use Rule: Any single-dose unit and remaining solution must be discarded immediately after a single use.
  • Disposal: Do not throw away medicines in wastewater or household waste. Consult a pharmacist regarding the proper local method for discarding unused or expired product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Colircusi Cicloplejico found in:

A-Z Index: